About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Tiotropium / Respimat One Year Study in COPD.

NCT00387088·334 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Boehringer Ingelheim

Age

40–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

1. Male or female
2. At least 40 years old
3. Smoker or ex-smoker
4. Smoking history \> 10 pack-years
5. Forced Expiratory Volume in 1 Second (FEV1) \< 60% predicted

You may not be if

1. Recent history of myocardial infarction, life-threatening cardiac arrhythmia or hospitalisation for cardiac failure
2. History of asthma or allergic conditions.
3. Malignancy requiring treatment within past 5 years
4. Life-threatening pulmonary obstruction, cystic fibrosis or clinically evident bronchiectasis
5. Known active tuberculosis
6. Known hypersensitivity to anticholinergic drugs.

The record

StatusCompleted

PhasePhase 3

Taking part3,991

StartedSep 2006

UpdatedMay 16, 2014

Conditions

Pulmonary Disease, Chronic Obstructive

Where334

205.372.01012 Boehringer Ingelheim Investigational Site
Birmingham, Alabama, United States
205.372.01020 Boehringer Ingelheim Investigational Site
Birmingham, Alabama, United States
205.372.01062 Boehringer Ingelheim Investigational Site
Mobile, Alabama, United States

Clareo Health | Tiotropium / Respimat One Year Study in COPD.